1 not yet recruiting, 1 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow AB248: new trials by email Literature Review of AB248 trials Research Report on AB248
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients Paclitaxel, Carboplatin, Pembrolizumab - Triple Negative Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 30 | 2026-12-01 | 2026-11-05 |
| A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) Tarlatamab, AB248 - Extensive Stage Small Cell Lung Cancer | Phase 1 | Recruiting | Amgen | 380 | 2025-09-16 | 2026-09-25 |
Triple Negative Breast Neoplasms (1)
Amgen (1) · Washington University School of Medicine (1)
United States (2) · South Korea (1) · Turkey (Türkiye) (1)